Medco, Abbott and Fujisawa tie up loose ends:
This article was originally published in Clinica
Medco Research and Abbott Laboratories have terminated their manufacturing and marketing agreements regarding Medco's newly-approved Adenoscan (adenosine injection) coronary vasodilator for thallium imaging (see Clinica No 656, p 18). The decision follows Medco and Fujisawa's (Japan) recent litigation settlement under which Fujisawa retains the manufacturing and marketing rights to Adenoscan in North America (see Clinica No 656, p 18). At the three companies' request, the US District Court for Northern Illinois dismissed their pending claims with prejudice. Other details of the termination agreement were not disclosed.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.